Miravirsen, which is developed using Locked Nucleic Acid (LNA) Drug Platform, is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication.
The randomized, double-blind, placebo-controlled, ascending multiple-dose Phase 2a study evaluated the safety and tolerability of miravirsen in treatment-naive patients with chronic HCV genotype 1 infection.
The trial demonstrated that miravirsen, a microRNA-targeted drug provided continuous and prolonged anti-viral activity and the patients infected with HCV could tolerat it.
As per the clinical data, miravirsen can be used as a once-weekly treatment for chronic HCV infection.